Meshel Laurie has got candid about her whopping 60kg weight loss as she called for a controversial obesity medication to be added to the Pharmaceutical Benefits Scheme (PBS).

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

First, a drug like Ozempic mimics the natural GLP-1 hormone in your gut, which slows down digestion in the stomach and ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Tack on a half-dozen zeros to your CVS receipt and you'll get a sense of the sticker shock afflicting state officials, insurers and hospitals dealing with the soaring cost of prescription drugs in ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Novo Nordisk A/S (NYSE: NVO) has reported that it retains about sixty percent of the list price of Ozempic and Wegovy, its ...

Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Many people stop taking GLP-1 drugs like Ozempic within a year, but doing so often leads to weight regain. Here's what to ...

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.